Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601546 | 0.87 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KMT2A | |
| SCHEMBL14534189 | 0.84 | OPRM1 (0.71) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL13284143 | 0.84 | OPRM1 (0.97) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL31117190 | 0.84 | ALDH1A1 (0.53) | OPRM1CHRM3KMT2A | |
| SCHEMBL4944766 | 0.84 | ALDH1A1 (0.57) | OPRM1CHRM3KMT2A | |
| SCHEMBL15765668 | 0.83 | OPRM1 (0.63) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL21726313 | 0.83 | ALDH1A1 (0.56) | OPRM1SLC6A4CHRM3SLC6A3KMT2A | |
| SCHEMBL31292357 | 0.83 | OPRM1 (0.63) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| SCHEMBL12227097 | 0.81 | OPRM1 (0.62) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A | |
| Hydrochloric Acid SCHEMBL2772455 | 0.81 | OPRM1 (0.66) | OPRM1OPRD1SLC22A1SLC6A4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-5760018-A | Gem-disubstituted azacyclic tachykinin antagonists | MERCK SHARP & DOHME LTD. (GB) | 1998-06-02 | — | — | US | disclosed |
| WO-1995019344-A1 | GEM-DISUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | OPRM1 4504/4885OPRD1 4376/4885SLC22A1 2418/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | OPRM1 4502/4885OPRD1 4379/4885SLC22A1 2449/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | OPRM1 4504/4885OPRD1 4376/4885SLC22A1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.